Ceftriaxone for alexander’s disease: A four-year follow-up

JIMD Reports

Volumn 9, Issue , 2013, Pages 67-71

  Sechi, GianPietro ^a   Ceccherini, Isabella ^b   Bachetti, Tiziana ^b   Deiana, Giovanni A ^a   Sechi, Elia ^a   Balbi, Pietro ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892722713     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_180     Document Type: Chapter

References (22)

1. Bachetti T, Di Zanni E, Balbi P et al (2010) In vitro treatments with ceftriaxone promote elimination of mutant glial fibrillary acidic protein and transcription down-regulation. Exp Cell Res 316:2152–2165
2. Balbi P, Salvini S, Fundarò C et al (2010) The clinical spectrum of late-onset Alexander disease: a systematic literature review. J Neurol 257:1955–1962
3. Brenner M, Johnson AB, Boesflug-Tanguy O, Rodriguez D, Goldman JE, Messing A (2001) Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27:117–120
4. Cho W, Brenner M, Peters N, Messing A (2010) Drug screening to identify suppressors of GFAP expression. Hum Mol Genet 19:3169–3178
5. Der Perng M, Su M, Wen SF et al (2006) The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and tha association of aB-crystallin and HSP27. Am J Hum Genet 79:197–213
6. Lapash Daniels CM, Austin EV, Rockney DE et al (2012) Beneficial effects of Nrf2 overexpression in a mouse model of Alexander disease. J Neurosci 32:10507–10515
7. Lewerenz J, Albrecht P, Tran Tien ML et al (2009) Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J Neurochem 111:332–343
8. Li R, Salomons G, Johnson AB, Naidu S et al (2005) Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 2005(57):310–326
9. Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M (1998) Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 152:391–398
10. Mignot C, Boespflug-Tanguy O, Gelot A, Dautigny A, Pham-Dinh D, Rodriguez D (2004) Alexander disease: putative mechanisms of an astrocytic encephalopathy. CMLS, Cell Mol Life Sci 61:369–385
11. Mignot C, Delarasse C, Escaich S et al (2007) Dynamics of mutated GFAP aggregates revealed by real-time imaging of an astrocyte model of Alexander disease. Exp Cell Res 313:2766–2779
12. Nau R, Prange HW, Muth P et al (1993) Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother 37:1518–1524
13. Rothstein JD, Patel S, Regan MR et al (2005) b-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433:73–77
14. Sawaishi Y (2009) Review of Alexander disease: beyond the classical concept of leukodystrophy. Brain Dev 31:493–498
15. Schwankhaus JD, Parisi JE, Gulledge WR, Chin L, Currier RD (1995) Hereditary adult-onset Alexander’s disease with palatal myoclonus, spastic paraparesis, and cerebellar ataxia. Neurology 45:2266–2271
16. Sechi GP, Matta M, Deiana GA et al (2010a) Ceftriaxone has a therapeutic role in Alexander disease. Prog Neuropsychopharmacol Biol Psychiatry 34:416–417
17. Sechi GP, Balbi P, Bachetti T, Ceccherini I (2010b) Correspondence regarding: Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol 69:1271–1272
18. Sechi GP, Balbi P, Bachetti T, Ceccherini I (2011) Safe drugs to fight mutant protein overload and alpha-1-antitrypsin deficiency. J Hepatol 55:949–950
19. Tang G, Perng MD, Wilk S, Quinlan R, Goldman JE (2010) Oligomers of mutant glial fibrillary acidic protein (GFAP) inhibit the proteasome system in Alexander disease astrocytes, and the small heat shock protein aB-crystallin reverse the inhibition. J Biol Chem 285:10527–10537
20. Tian R, Wu X, Hagemann TL, Sosunov AA, Messing A, McKham GM, Goldman JE (2010) Alexander disease mutant glial fibrillary acidic protein compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol 69:335–345
21. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607
22. Yamada J, Jinno S (2011) Alterations in neuronal survival and glial reactions after axotomy by ceftriaxone and minocycline in the mouse hypoglossal nucleus. Neurosci Lett. doi:10.1016/j. neulet.2011. 09.051